|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM312441622 |
| 003 |
DE-627 |
| 005 |
20250227144406.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202002661
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1041.xml
|
| 035 |
|
|
|a (DE-627)NLM312441622
|
| 035 |
|
|
|a (NLM)32667701
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhang, Yan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Photoactivatable Protherapeutic Nanomedicine for Cancer
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.06.2021
|
| 500 |
|
|
|a Date Revised 18.06.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
| 520 |
|
|
|a Therapeutic systems with site-specific pharmaceutical activation hold great promise to enhance therapeutic efficacy while reducing systemic toxicity in cancer therapy. With operational flexibility, noninvasiveness, and high spatiotemporal resolution, photoactivatable nanomedicines have drawn growing attention. Distinct from traditional controlled release systems relying on the difference of biomarker concentrations between disease and healthy tissues, photoactivatable nanomedicines capitalize on the interaction between nanotransducers and light to either trigger photochemical reactions or generate reactive oxygen species (ROS) or heat effect to remotely induce pharmaceutical actions in living subjects. Herein, the recent advances in the development of photoactivatable protherapeutic nanoagents for oncology are summarized. The design strategies and therapeutic applications of these nanoagents are described. Representative examples of each type are discussed in terms of structure, photoactivation mechanism, and preclinical models. Last, potential challenges and perspectives to further develop photoactivatable protherapeutic nanoagents in cancer nanomedicine are discussed
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a cancer therapy
|
| 650 |
|
4 |
|a nanoparticles
|
| 650 |
|
4 |
|a photoactivatable nanomedicines
|
| 650 |
|
4 |
|a phototherapy
|
| 650 |
|
4 |
|a protherapeutics
|
| 700 |
1 |
|
|a Xu, Cheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Xiangliang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pu, Kanyi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 32(2020), 34 vom: 08. Aug., Seite e2002661
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:32
|g year:2020
|g number:34
|g day:08
|g month:08
|g pages:e2002661
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202002661
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 32
|j 2020
|e 34
|b 08
|c 08
|h e2002661
|